Výsledky vyhledávání - "Steven Hubert"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection

Autor: Steven Hubert, John F. Kokai-Kun, Giovanni Widmer, Annie Jones, Todd Parsley, Nur A. Hasan, Sheila Connelly, Perrti Koski, J. Andrew Bristol, Michael Kaleko, Saul Tzipori, Poorani Subramanian, Joseph Sliman

Publikováno v: Anaerobe. 41:58-67

The gut microbiome, composed of the microflora that inhabit the gastrointestinal tract and their genomes, make up a complex ecosystem that can be disrupted by antibiotic use. The ensuing dysbiosis is conducive to the emergence of opportunistic pathog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcd00bc23048fef79afda3d09e5e11d1

Zobrazit plný text záznamu

Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies

Autor: J. Andrew Bristol, Heidi Whalen, John F. Kokai-Kun, Joseph Sliman, Kenneth C. Lasseter, Olivia Coughlin, Tracey Roberts, Steven Hubert, Barbara Valero Lopez, James Longstreth

Publikováno v: Clinical Drug Investigation. 36:725-734

SYN-004 is an orally administered β-lactamase enzyme, designed to be given concurrently with certain intravenous β-lactam antibiotics like cephalosporins. SYN-004 is intended to degrade residual antibiotics excreted into the intestine as a result o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e1f60974d01086422b6d69cce43c547
https://doi.org/10.1007/s40261-016-0420-0

Zobrazit plný text záznamu

News

Steven Hubert Joins Omnia Biologics

Autor: Omnia Biologics, Inc.

Publikováno v: Business Wire (English). 03/15/2011.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Formulation development of SYN-004 (ribaxamase) oral solid dosage form, a β-lactamase to prevent intravenous antibiotic-associated dysbiosis of the colon

Autor: Felix Hofmann, Hans Baer, Andrew Bristol, Steven Hubert

Publikováno v: International journal of pharmaceutics. 534(1-2)

SYN-004 (ribaxamase) delayed release drug product is a multi-particulate, hard capsule for oral delivery of a recombinant β-lactamase enzyme designed to degrade β-lactam antibiotics administered intravenously, and thus prevent colon dysbiosis. Here

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29cc37caa94f380793f4995569b3a718
https://pubmed.ncbi.nlm.nih.gov/28986322

Zobrazit plný text záznamu

Development of a Modified-Release Formulation of Lovastatin Targeted to Intestinal Methanogens Implicated in Irritable Bowel Syndrome With Constipation

Autor: Steven Hubert, Alan Chadwick, Andrew Bristol, Olivia Coughlin, Vince Wacher, John F. Kokai-Kun

Publikováno v: Journal of pharmaceutical sciences. 107(2)

There is growing evidence that methane production, predominantly by Methanobrevibacter smithii , in the intestines is a cause of constipation, pain, and bloating in irritable bowel syndrome with constipation (IBS-C). M smithii resides primarily in th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41706283ae237c0fcbbac3f0bca67b2f
https://pubmed.ncbi.nlm.nih.gov/28989013

Zobrazit plný text záznamu